10x Genomics (NASDAQ:TXG) Releases Earnings Results, Beats Estimates By $0.19 EPS

10x Genomics (NASDAQ:TXG) announced its quarterly earnings data on Thursday. The company reported ($0.10) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.19, FiscalAI reports. The business had revenue of $150.84 million for the quarter, compared to analyst estimates of $146.41 million. 10x Genomics had a negative return on equity of 6.89% and a negative net margin of 6.77%.The company’s revenue was up 9.4% on a year-over-year basis. During the same period in the prior year, the company earned ($0.28) earnings per share.

Here are the key takeaways from 10x Genomics’ conference call:

• Atera launch is the company’s largest product introduction, enabling spatial whole-transcriptome with single-cell sensitivity at scale and generating “extraordinary” early customer interest and pre-orders ahead of initial H2 2026 shipments.
• Consumables and margins showed strength in Q1 — revenue was $150.8M (up ~9% YoY excluding a one-time settlement), total consumables +13% (spatial consumables +31%), gross margin 70%, and cash balance of $540M (+$113M YoY).
• Instrument revenue declined materially (total instruments -24%, spatial instruments -32%), and management expects a Q2 sequential step-down as some customers delay purchases waiting for Atera; Atera production capacity will be limited in 2026 with roughly ~40 units expected between Q3–Q4.
• Company is positioning for a structural AI and translational tailwind — multiple partnerships and initiatives (e.g., Chan Zuckerberg, Bioptimus) aim to scale biological data generation, expanding the long-term TAM but with uncertain near-term revenue timing.

10x Genomics Stock Down 3.7%

Shares of TXG traded down $0.82 during mid-day trading on Friday, reaching $21.60. The company had a trading volume of 4,830,326 shares, compared to its average volume of 2,612,894. The stock has a market capitalization of $2.76 billion, a P/E ratio of -61.71 and a beta of 2.05. The stock has a 50 day moving average of $21.53 and a two-hundred day moving average of $18.96. 10x Genomics has a 52-week low of $8.06 and a 52-week high of $26.44.

Key Headlines Impacting 10x Genomics

Here are the key news stories impacting 10x Genomics this week:

• Positive Sentiment: 10x Genomics reported Q1 revenue of $150.8 million and EPS of -$0.10, both better than Wall Street expectations, with revenue up 9.4% year over year and gross margin improving. Article: 10x Genomics Q1 Earnings & Revenues Beat Estimates, Gross Margin Up
• Positive Sentiment: William Blair reiterated a Buy rating, citing strong Q1 results, an improved growth outlook tied to Atera, and attractive valuation. Article: 10x Genomics: Buy Rating Reaffirmed on Strong Q1, Atera-Driven Growth Outlook, and Attractive Valuation
• Neutral Sentiment: The company’s earnings call transcript and earnings coverage are drawing attention as investors look for more detail on management’s plans and the sustainability of margin improvement. Article: 10x Genomics, Inc. (TXG) Q1 2026 Earnings Call Transcript
• Negative Sentiment: Despite the beat, 10x Genomics still posted a loss and remains unprofitable, and the company’s FY2026 revenue outlook of $600 million to $625 million is only modestly above consensus. Article: 10x Genomics Reports First Quarter 2026 Financial Results

Insiders Place Their Bets

In other 10x Genomics news, insider Benjamin J. Hindson sold 7,826 shares of the stock in a transaction that occurred on Monday, February 23rd. The stock was sold at an average price of $18.58, for a total transaction of $145,407.08. Following the transaction, the insider owned 424,779 shares in the company, valued at approximately $7,892,393.82. This represents a 1.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Adam Taich sold 8,968 shares of the stock in a transaction that occurred on Monday, February 23rd. The stock was sold at an average price of $18.58, for a total value of $166,625.44. Following the transaction, the chief financial officer owned 288,417 shares in the company, valued at $5,358,787.86. This represents a 3.02% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 46,426 shares of company stock worth $902,695. 8.84% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On 10x Genomics

Hedge funds have recently bought and sold shares of the business. Van ECK Associates Corp boosted its position in 10x Genomics by 85.9% during the fourth quarter. Van ECK Associates Corp now owns 3,668 shares of the company’s stock worth $60,000 after purchasing an additional 1,695 shares in the last quarter. EverSource Wealth Advisors LLC boosted its position in 10x Genomics by 203.9% during the second quarter. EverSource Wealth Advisors LLC now owns 7,490 shares of the company’s stock worth $87,000 after purchasing an additional 5,025 shares in the last quarter. Focus Partners Wealth purchased a new position in 10x Genomics during the first quarter worth approximately $92,000. CIBC Bancorp USA Inc. purchased a new position in 10x Genomics during the third quarter worth approximately $134,000. Finally, EP Wealth Advisors LLC purchased a new position in 10x Genomics during the fourth quarter worth approximately $188,000. Hedge funds and other institutional investors own 84.68% of the company’s stock.

Analyst Ratings Changes

TXG has been the topic of a number of recent research reports. Stifel Nicolaus upped their target price on 10x Genomics from $20.00 to $25.00 and gave the stock a “buy” rating in a research note on Monday, March 2nd. UBS Group upped their target price on 10x Genomics from $14.00 to $20.00 and gave the stock a “neutral” rating in a research note on Friday, February 20th. Canaccord Genuity Group upped their target price on 10x Genomics from $22.00 to $32.00 and gave the stock a “buy” rating in a research note on Monday, April 20th. William Blair upgraded 10x Genomics from a “market perform” rating to an “outperform” rating in a research note on Tuesday, March 31st. Finally, Leerink Partners lowered their target price on 10x Genomics from $22.00 to $20.00 and set a “market perform” rating on the stock in a research note on Tuesday, January 27th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, nine have issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, 10x Genomics currently has an average rating of “Hold” and a consensus price target of $20.82.

About 10x Genomics

10x Genomics, Inc is a biotechnology company specializing in advanced genomic analysis solutions that enable researchers to explore biology at unprecedented resolution. The company develops and manufactures integrated hardware, consumables and software products for single-cell sequencing and spatial genomics. Its flagship Chromium product line supports applications in single-cell RNA sequencing, immune profiling and genome assembly, while the Visium and Xenium platforms offer spatial transcriptomics and in situ analysis, respectively.

Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves a global customer base that includes academic institutions, pharmaceutical and biotechnology companies, and government research organizations.